Measurement of Pro-resolving Inflammation Biomarkers in Saliva, Gingival Fluid, and Dental Pulp in Patients With Symptomatic Pulpitis and Healthy Controls
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Pulpitis, Healthy. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Strategic Inflammation Modulation and Advanced Regenerative Therapy of Dental PULP
Overview
This observational study aims to better understand inflammation inside the dental pulp (the inner tissue of the tooth) in patients with symptomatic pulpitis compared with healthy individuals. Researchers will measure inflammation-related biomarkers in saliva, gingival fluid, and dental pulp samples to determine whether these substances reflect the level of inflammation. The study also evaluates whether saliva and oral fluids could be used as simple, non-invasive tools to detect and monitor pulp inflammation. We hypothesize that patients with pulpitis will show different biomarker levels compared with healthy controls.
Primary outcome measures
- Measurement Compare LXA4 and RvE1 levels in saliva, gingival crevicular fluid, and dental pulp in patients with dental pulpitis and healthy subjects. [Time frame: Day 0 (initial visit)]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years, male or female.
- Patient consulting for symptomatic pulpitis (confirmed clinical and radiographic diagnosis) or for wisdom tooth extraction (healthy subject).
- Patient able to understand the research and having signed a written consent form.
- Permanent teeth only.
Exclusion criteria
- Refusal to participate.
- Pregnancy or breastfeeding.
- Antibiotic or anti-inflammatory treatment in the week prior to sampling.
- Clinically diagnosed inflammatory gingival or periodontal disease (gingivitis or periodontitis)
- Chronic systemic inflammatory disease (e.g., uncontrolled diabetes, autoimmune diseases).
- Patients under guardianship, conservatorship, or legal protection
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Nantes University Hospital Dental Clinic — Nantes
Publications
- Khoshbin E, Salehi R, Behroozi R, Sadr S, Zamani A, Farhadian M, Karkehabadi H. The effect of low-dose aspirin on aspirin triggered lipoxin, interleukin 1 beta, and prostaglandin E2 levels in periapical fluid: a double-blind randomized clinical trial. BMC Oral Health. 2023 Jul 31;23(1):530. doi: 10.1186/s12903-023-03243-0. PMID 37525211
Identifiers
NCT: NCT07450235 · GNEDS-AVIS-25-116-12-030